JP2019518767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518767A5 JP2019518767A5 JP2018566969A JP2018566969A JP2019518767A5 JP 2019518767 A5 JP2019518767 A5 JP 2019518767A5 JP 2018566969 A JP2018566969 A JP 2018566969A JP 2018566969 A JP2018566969 A JP 2018566969A JP 2019518767 A5 JP2019518767 A5 JP 2019518767A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- independently
- pharmaceutically acceptable
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 117
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 239000011593 sulfur Substances 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 150000002431 hydrogen Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 206010003571 Astrocytoma Diseases 0.000 claims description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- 229910052805 deuterium Inorganic materials 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- -1 -CH 2 - Chemical group 0.000 claims description 6
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 6
- 206010014967 Ependymoma Diseases 0.000 claims description 6
- 208000000172 Medulloblastoma Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 206010065869 Astrocytoma, low grade Diseases 0.000 claims description 4
- 206010006143 Brain stem glioma Diseases 0.000 claims description 4
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 4
- 206010073338 Optic glioma Diseases 0.000 claims description 4
- 208000007641 Pinealoma Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 208000008511 optic nerve glioma Diseases 0.000 claims description 4
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 2
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 2
- 208000001662 Subependymal Glioma Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 210000000860 cochlear nerve Anatomy 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 2
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 2
- 208000006971 mastocytoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000004058 mixed glioma Diseases 0.000 claims description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 208000030819 subependymoma Diseases 0.000 claims description 2
- 0 C*CCCC1(C)CNCCC1 Chemical compound C*CCCC1(C)CNCCC1 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- AEMSRNHLEUPYQI-UHFFFAOYSA-N CCCC1NCC(CCC2)N2C1 Chemical compound CCCC1NCC(CCC2)N2C1 AEMSRNHLEUPYQI-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N c1cnc2[n]1cccc2 Chemical compound c1cnc2[n]1cccc2 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N c1nc2ccccc2[nH]1 Chemical compound c1nc2ccccc2[nH]1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022051875A JP7402549B2 (ja) | 2016-06-21 | 2022-03-28 | Cxcr4阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352820P | 2016-06-21 | 2016-06-21 | |
| US62/352,820 | 2016-06-21 | ||
| US201762456526P | 2017-02-08 | 2017-02-08 | |
| US62/456,526 | 2017-02-08 | ||
| PCT/US2017/038609 WO2017223239A1 (en) | 2016-06-21 | 2017-06-21 | Cxcr4 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022051875A Division JP7402549B2 (ja) | 2016-06-21 | 2022-03-28 | Cxcr4阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518767A JP2019518767A (ja) | 2019-07-04 |
| JP2019518767A5 true JP2019518767A5 (cg-RX-API-DMAC7.html) | 2020-07-16 |
| JP7054529B2 JP7054529B2 (ja) | 2022-04-14 |
Family
ID=60783547
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566969A Active JP7054529B2 (ja) | 2016-06-21 | 2017-06-21 | Cxcr4阻害剤およびその使用 |
| JP2022051875A Active JP7402549B2 (ja) | 2016-06-21 | 2022-03-28 | Cxcr4阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022051875A Active JP7402549B2 (ja) | 2016-06-21 | 2022-03-28 | Cxcr4阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10759796B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3808748B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7054529B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116554168B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3027498A1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2870920T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017223239A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US11497744B2 (en) | 2017-02-21 | 2022-11-15 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| EP3768256A4 (en) | 2018-03-19 | 2021-11-24 | Emory University | PAN-TROPICAL ENTRANCE INHIBITORS |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020264292A1 (en) * | 2019-06-26 | 2020-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物 |
| WO2021065898A1 (ja) | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | アゼパン誘導体 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN115515585A (zh) | 2020-03-10 | 2022-12-23 | X4 制药有限公司 | 用于治疗中性粒细胞减少症的方法 |
| WO2021263203A1 (en) * | 2020-06-26 | 2021-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2023003862A1 (en) | 2021-07-19 | 2023-01-26 | Emory University | Cxcr4 modulators and uses related thereto |
| EP4444304A4 (en) * | 2021-12-09 | 2025-12-17 | X4 Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF PRIMARY IMMUNE DISCOMFORT |
| US20250326753A1 (en) * | 2022-03-25 | 2025-10-23 | X4 Pharmaceuticals, Inc. | Dual cxcr4-btk inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
| EP4608508A1 (en) * | 2022-10-26 | 2025-09-03 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors for treatment of neurological diseases |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| WO1997009976A2 (en) | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| SK127398A3 (en) | 1996-03-22 | 1999-04-13 | Du Pont Pharm Co | Novel asymmetric synthesis of r-'alpha'-propyl-piperonyl amine and its analogs |
| IL133212A (en) | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| WO1999016747A1 (en) | 1997-09-30 | 1999-04-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| GB9726229D0 (en) | 1997-12-12 | 1998-02-11 | Zeneca Ltd | Resolution of chiral amines |
| WO1999032100A2 (en) | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| US6607799B1 (en) | 1998-10-15 | 2003-08-19 | 3M Innovative Properties Company | Surgical dressing with delivery system and method of manufacture |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| IL145401A0 (en) | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| MXPA02004555A (es) | 1999-11-08 | 2004-09-10 | Wyeth Corp | Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central. |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR20030034184A (ko) | 2000-09-15 | 2003-05-01 | 아노르메드 인코포레이티드 | 케모킨 수용체 결합 헤테로사이클릭 화합물 |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| RU2289581C2 (ru) | 2000-09-15 | 2006-12-20 | Анормед, Инк. | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| CN102302493B (zh) | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | 活化祖细胞/干细胞的方法 |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| EP1487795B1 (en) | 2001-09-12 | 2010-11-03 | Anormed Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| CA2467718C (en) | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7491544B2 (en) | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| CA2520259A1 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| RU2005136224A (ru) | 2003-04-22 | 2006-06-10 | Анормед Инк. (Ca) | Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| US7332605B2 (en) | 2004-03-15 | 2008-02-19 | Anormed, Inc. | Process for the synthesis of CXCR4 antagonist |
| AU2005233632A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TW200612935A (en) | 2004-08-02 | 2006-05-01 | Smithkline Beecham Corp | Chemical compounds |
| PE20060646A1 (es) | 2004-08-16 | 2006-08-04 | Smithkline Beecham Corp | Derivados de bencimidazol como moduladores de la actividad de quimioquinas |
| EP1799671A4 (en) | 2004-09-02 | 2009-06-10 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| WO2006036816A2 (en) | 2004-09-24 | 2006-04-06 | Smithkline Beecham Corporation | Chemical compounds |
| TW200619206A (en) | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006096444A2 (en) | 2005-03-04 | 2006-09-14 | Smithkline Beecham Corporation | Chemical compounds |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007006408A2 (en) | 2005-07-08 | 2007-01-18 | Bayer Healthcare Ag | Methods and kits for predicting and monitoring direct response to cancer therapy |
| US20080214562A1 (en) | 2005-07-11 | 2008-09-04 | Kristjan Gudmundsson | Chemical Compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| JP5535480B2 (ja) | 2005-08-02 | 2014-07-02 | イネオス ユーロープ リミテッド | ジエン重合 |
| US20070043012A1 (en) | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| US20080234318A1 (en) | 2005-08-31 | 2008-09-25 | Kristjan Gudmundsson | Chemical Compounds |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| JP2009517474A (ja) | 2005-11-30 | 2009-04-30 | シェーリング コーポレイション | Ccr5拮抗剤およびcxcr4拮抗剤の組み合わせを含む組成物 |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AR059197A1 (es) | 2006-01-25 | 2008-03-19 | Smithkline Beecham Corp | Derivados de indazolo piridina para el tratamiento de hiv |
| WO2007087548A2 (en) * | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
| GB0605786D0 (en) | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| KR20090013827A (ko) | 2006-06-12 | 2009-02-05 | 화이자 프로덕츠 인크. | Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| WO2008141239A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| WO2009026251A1 (en) | 2007-08-17 | 2009-02-26 | The General Hospital Corporation | Detecting ions and measuring ion concentrations |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| EP2234487A4 (en) | 2007-12-19 | 2011-09-07 | Scripps Research Inst | ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| KR20110014141A (ko) | 2008-03-20 | 2011-02-10 | 카롤러스 테라퓨틱스, 인코포레이티드 | 염증을 치료하는 방법 |
| KR20110005819A (ko) | 2008-03-28 | 2011-01-19 | 알티리스 쎄라퓨틱스 | 케모카인 수용체 조절제 |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2010016628A (ja) | 2008-07-03 | 2010-01-21 | Canon Inc | 画像処理装置及び画像処理方法 |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| US9119790B2 (en) | 2009-09-28 | 2015-09-01 | Zenbury International Limited | Pharmaceutical composition |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US20110295365A1 (en) | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| CA2706292A1 (en) | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| AU2011336397B2 (en) | 2010-12-03 | 2016-12-15 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| EP2648754A4 (en) * | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHOD OF INHIBITING CANCER METASTASES |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2821985C (en) | 2011-01-11 | 2019-07-09 | Dimerix Bioscience Pty Ltd | Combination therapy |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| CN103814024B (zh) | 2011-09-26 | 2016-11-23 | 默克专利股份公司 | 作为溶血磷脂酸(lpa)受体拮抗剂的苄基哌啶化合物 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2860995A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| CA2892490A1 (en) | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| HK1219044A1 (zh) * | 2013-03-15 | 2017-03-24 | 艾伯维德国有限责任两合公司 | 抗egfr抗体药物偶联物制剂 |
| BR112015030518A2 (pt) | 2013-06-05 | 2017-08-29 | Salk Inst For Biological Studi | Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12) |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| US10280183B2 (en) | 2014-03-18 | 2019-05-07 | The Research Foundation For The State University Of New York | Therapeutic agent for treating tumors |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| KR20170105514A (ko) | 2014-12-12 | 2017-09-19 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | 알파 9 인테그린 길항제 및 cxcr4 길항제를 사용한 hsc의 이탈 및 방출 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10379661B2 (en) | 2015-09-25 | 2019-08-13 | Samsung Electronics Co., Ltd. | Coordinate measuring apparatus and coordinate measuring system having the same |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| EP3405203A4 (en) | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3443013B1 (en) | 2016-04-14 | 2025-01-22 | Creatv Microtech, Inc. | Methods of using pd-l1 expression in treatment decisions for cancer therapy |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
| CA3066778A1 (en) | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP2021502071A (ja) | 2017-11-07 | 2021-01-28 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がんバイオマーカーおよびその使用方法 |
| CA3085763A1 (en) | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| JP2021521439A (ja) | 2018-04-13 | 2021-08-26 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
-
2017
- 2017-06-21 EP EP20212271.9A patent/EP3808748B1/en active Active
- 2017-06-21 CN CN202310296466.XA patent/CN116554168B/zh active Active
- 2017-06-21 ES ES17816163T patent/ES2870920T3/es active Active
- 2017-06-21 CA CA3027498A patent/CA3027498A1/en active Pending
- 2017-06-21 JP JP2018566969A patent/JP7054529B2/ja active Active
- 2017-06-21 ES ES20212271T patent/ES3073807T3/es active Active
- 2017-06-21 CN CN201780048803.6A patent/CN109562106B/zh active Active
- 2017-06-21 WO PCT/US2017/038609 patent/WO2017223239A1/en not_active Ceased
- 2017-06-21 US US16/311,020 patent/US10759796B2/en active Active
- 2017-06-21 EP EP17816163.4A patent/EP3471727B1/en active Active
-
2020
- 2020-07-27 US US16/939,723 patent/US11306088B2/en active Active
-
2022
- 2022-03-14 US US17/654,722 patent/US11780837B2/en active Active
- 2022-03-28 JP JP2022051875A patent/JP7402549B2/ja active Active
-
2023
- 2023-09-12 US US18/465,823 patent/US20240150350A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524665A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518768A5 (cg-RX-API-DMAC7.html) | ||
| RU2012118667A (ru) | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 | |
| JP2013506715A5 (cg-RX-API-DMAC7.html) | ||
| AR038202A1 (es) | Compuestos de indazol utiles como inhibidores de la proteina quinasa | |
| JP2021522237A5 (cg-RX-API-DMAC7.html) | ||
| AU2005222995B2 (en) | Immune response modifier formulations and methods | |
| JP2008526752A (ja) | 免疫応答調節剤化合物の多経路投与 | |
| SI2736887T1 (en) | Hydrazide containing nuclear transport modulators and uses thereof | |
| RU2013156361A (ru) | Новые соединения | |
| HUP0003386A2 (hu) | CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
| AU2015306662A1 (en) | Compounds and methods for inhibiting histone demethylases | |
| AU2008258188A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
| RU2002129354A (ru) | Производные этилендиамина | |
| JP2005524631A5 (cg-RX-API-DMAC7.html) | ||
| RU2016118399A (ru) | Производные 4-аминометилбензойной кислоты | |
| JP2019502763A5 (cg-RX-API-DMAC7.html) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| CA2709806A1 (en) | Protein kinase inhibitors and use thereof | |
| JP2013503905A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502092A5 (cg-RX-API-DMAC7.html) | ||
| JP2022500499A5 (cg-RX-API-DMAC7.html) | ||
| CN110386941A (zh) | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 | |
| JP2024031964A (ja) | 抗sez6抗体薬物複合体 | |
| JP2014504648A5 (cg-RX-API-DMAC7.html) |